<DOC>
	<DOC>NCT00532233</DOC>
	<brief_summary>The purpose of this study is to investigate how QAX576 affects levels of interleukin 13 (IL-13) in patients with idiopathic pulmonary fibrosis (IPF).</brief_summary>
	<brief_title>SD, IL-13 Production Rate in IPF</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Men and women between the ages of 40 and 80 years with a confirmed diagnosis of idiopathic pulmonary fibrosis Both men and women must be on nonchildbearing potential. Additional information regarding this requirement is available at screening. Capability to meet certain lung function tests at screening Nonsmokers No participation in another clinical study within 4 weeks of study start. Certain medical conditions may exclude candidates from participation. Blood loss or donation of 400 mL or more within 2 months of study start Significant illness (other than respiratory) within 2 weeks of study start Past medical personal or close family history of clinically significant ECG abnormalities Connective tissue disorders Active infection or history of systemic parasitic infection Known hypersensitivity to the drug. History of immunocompromise, including a positive HIV test result. History of drug or alcohol abuse within 12 months of study start Any condition that may compromise patient safety</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Idiopathic Pulmonary Fibrosis</keyword>
</DOC>